Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
222 hedge funds and large institutions have $3.05B invested in Amicus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 73 increasing their positions, 72 reducing their positions, and 22 closing their positions.
61% more call options, than puts
Call options by funds: $8.09M | Put options by funds: $5.04M
59% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 22
5% more funds holding
Funds holding: 212 → 222 (+10)
1% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 72
4.69% less ownership
Funds ownership: 108.94% → 104.24% (-4.7%)
7% less capital invested
Capital invested by funds: $3.28B → $3.05B (-$229M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$31.7M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$16.8M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$9.85M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.29M |
| 5 |
Goldman Sachs
New York
|
+$7.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$52.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.1M |
| 3 |
Janus Henderson Group
London,
|
-$22.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$21.2M |
| 5 |
State Street
Boston,
Massachusetts
|
-$21.1M |
FOLD Hedge Fund Activity: Q3 2022 in Review
222 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2022, worth a combined $3.05B — down 7% from $3.28B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new FOLD positions and 22 closed out — a net gain of 13 holders — while 73 added to existing stakes and 72 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), adding an estimated $31.7M. The largest seller was Deutsche Bank, cutting an estimated $52.7M.
- 222 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2022, up from 212 in Q2 2022.
- Funds reported $3.05B of Amicus Therapeutics stock for Q3 2022, down 7% quarter-over-quarter.
- 35 funds opened new Amicus Therapeutics positions in Q3 2022 and 22 closed out, a net change of +13 holders.
- The largest Amicus Therapeutics buyer in Q3 2022 was Pictet Asset Management (Switzerland), an estimated $31.7M added.
- The largest Amicus Therapeutics seller in Q3 2022 was Deutsche Bank, an estimated $52.7M sold.
Based on aggregated 13F filings for Q3 2022.